AZD-8421 Drug Asset Due Diligence Report 2026

This AZD-8421 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 11 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 1/2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether AZD-8421 can convert its Small molecule drug profile and CDK2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	AZD-8421 (query alias: AZD-8421)
Modality / target	Small molecule drug; CDK2; CDK2 inhibitors
Highest global status	Phase 1/2
Originator	AstraZeneca PLC
Active developers	AstraZeneca AB, AstraZeneca PLC, Emory University

The MCP disease footprint includes Metastatic Solid Tumor, ER-positive/HER2-negative Breast Cancer, high grade serous adenocarcinoma of ovary. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06188520	Phase 1/2	Recruiting	564	Primary endpoint not disclosed in English source
CTIS2023-507305-33-00	Phase 1/2	Recruiting	564	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Abstract ND06: First disclosure of AZD8421, a highly selective CDK2 inhibitor to address resistance to CDK4/6 inhibitors in breast and CCNE1-high cancers

Phase 1/2; n=not disclosed; evaluation: Not stated in English source. Reported fields: IC50 = 9 nm ; Residence time = 7 Hour

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

AZD-8421 addresses Metastatic Solid Tumor, ER-positive/HER2-negative Breast Cancer, high grade serous adenocarcinoma of ovary. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 16 matched transaction record(s) under the scope “target-level comparable: CDK2.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: CDK2 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2025-07-02	Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001	Phase 1	Financial terms not disclosed
2025-06-25	Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders	Preclinical	US$85.0M upfront; US$750.0M stated total
2024-10-01	Genentech buys Regor’s CDK inhibitors in $850m deal	Phase 1	US$850.0M upfront

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Crystalline form of (s)-n-ethyl-3-((9-ethyl-2-(((2r,3s)-2-hydroxypentan-3-YL)amino)-9h-purin-6-YL)amino)-pyrrolidine-1-sulfonamide”. The milestone feed surfaced a patent-application signal described as “CDK inhibitors conjugated to EGFR targeting moieties”. The milestone feed surfaced a patent-application signal described as “Preparation method of AZD-8421 and intermediate thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO